Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
Outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with unresectable pancreatic cancer treated with GnP after first-line mFFX treatment...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/2/358 |
| _version_ | 1797444945604247552 |
|---|---|
| author | Takafumi Mie Takashi Sasaki Tsuyoshi Takeda Takeshi Okamoto Tsuyoshi Hamada Takahiro Ishitsuka Manabu Yamada Hiroki Nakagawa Takaaki Furukawa Akiyoshi Kasuga Masato Matsuyama Masato Ozaka Naoki Sasahira |
| author_facet | Takafumi Mie Takashi Sasaki Tsuyoshi Takeda Takeshi Okamoto Tsuyoshi Hamada Takahiro Ishitsuka Manabu Yamada Hiroki Nakagawa Takaaki Furukawa Akiyoshi Kasuga Masato Matsuyama Masato Ozaka Naoki Sasahira |
| author_sort | Takafumi Mie |
| collection | DOAJ |
| description | Outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with unresectable pancreatic cancer treated with GnP after first-line mFFX treatment between March 2015 and March 2022 at our hospital. A total of 103 patients were included. Median overall survival (OS) from the start of first-line and second-line treatments was 14.9 months and 7.2 months, respectively. Median progression-free survival (PFS) was 3.6 months. Performance status, modified Glasgow prognostic score, and neutrophil-to-lymphocyte ratio were independently associated with OS. Our prognostic model using these parameters classifies patients into good (n = 70) and poor (n = 33) prognosis groups. Median OS and PFS were longer in the good prognosis group than in the poor prognosis group (OS: 9.3 vs. 3.8 months, <i>p</i> < 0.01; PFS: 4.1 vs. 2.3 months, <i>p</i> < 0.01). Grade 3/4 adverse events were observed in 70.9% of patients, with neutropenia being the most frequent. While GnP as second-line treatment was well-tolerated, efficacy of second-line gemcitabine plus nab-paclitaxel was notably limited, particularly in the poor prognosis group. |
| first_indexed | 2024-03-09T13:18:47Z |
| format | Article |
| id | doaj.art-b83bcc8de4c14e07824d1ca96c6055a4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:18:47Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b83bcc8de4c14e07824d1ca96c6055a42023-11-30T21:32:45ZengMDPI AGCancers2072-66942023-01-0115235810.3390/cancers15020358Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic CancerTakafumi Mie0Takashi Sasaki1Tsuyoshi Takeda2Takeshi Okamoto3Tsuyoshi Hamada4Takahiro Ishitsuka5Manabu Yamada6Hiroki Nakagawa7Takaaki Furukawa8Akiyoshi Kasuga9Masato Matsuyama10Masato Ozaka11Naoki Sasahira12Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanOutcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with unresectable pancreatic cancer treated with GnP after first-line mFFX treatment between March 2015 and March 2022 at our hospital. A total of 103 patients were included. Median overall survival (OS) from the start of first-line and second-line treatments was 14.9 months and 7.2 months, respectively. Median progression-free survival (PFS) was 3.6 months. Performance status, modified Glasgow prognostic score, and neutrophil-to-lymphocyte ratio were independently associated with OS. Our prognostic model using these parameters classifies patients into good (n = 70) and poor (n = 33) prognosis groups. Median OS and PFS were longer in the good prognosis group than in the poor prognosis group (OS: 9.3 vs. 3.8 months, <i>p</i> < 0.01; PFS: 4.1 vs. 2.3 months, <i>p</i> < 0.01). Grade 3/4 adverse events were observed in 70.9% of patients, with neutropenia being the most frequent. While GnP as second-line treatment was well-tolerated, efficacy of second-line gemcitabine plus nab-paclitaxel was notably limited, particularly in the poor prognosis group.https://www.mdpi.com/2072-6694/15/2/358pancreatic cancersecond-line treatmentgemcitabine plus nab-paclitaxel |
| spellingShingle | Takafumi Mie Takashi Sasaki Tsuyoshi Takeda Takeshi Okamoto Tsuyoshi Hamada Takahiro Ishitsuka Manabu Yamada Hiroki Nakagawa Takaaki Furukawa Akiyoshi Kasuga Masato Matsuyama Masato Ozaka Naoki Sasahira Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer Cancers pancreatic cancer second-line treatment gemcitabine plus nab-paclitaxel |
| title | Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer |
| title_full | Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer |
| title_fullStr | Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer |
| title_full_unstemmed | Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer |
| title_short | Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer |
| title_sort | treatment outcomes and prognostic factors of gemcitabine plus nab paclitaxel as second line chemotherapy after modified folfirinox in unresectable pancreatic cancer |
| topic | pancreatic cancer second-line treatment gemcitabine plus nab-paclitaxel |
| url | https://www.mdpi.com/2072-6694/15/2/358 |
| work_keys_str_mv | AT takafumimie treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT takashisasaki treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT tsuyoshitakeda treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT takeshiokamoto treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT tsuyoshihamada treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT takahiroishitsuka treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT manabuyamada treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT hirokinakagawa treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT takaakifurukawa treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT akiyoshikasuga treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT masatomatsuyama treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT masatoozaka treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer AT naokisasahira treatmentoutcomesandprognosticfactorsofgemcitabineplusnabpaclitaxelassecondlinechemotherapyaftermodifiedfolfirinoxinunresectablepancreaticcancer |